Global Therapeutic Biologics Market 2022-2028

September 2022 | 75 pages | ID: G8037B87BDFFEN
Gen Consulting Company

Abstracts

According to latest analysis by Gen Consulting Company, the global therapeutic biologics market is poised to grow by USD 170 billion during 2022-2028, progressing at a CAGR of 7.7% during the forecast period.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global therapeutic biologics market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the therapeutic biologics industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, and region. The global market for therapeutic biologics can be segmented by product: therapeutic proteins, vaccines, others. Among these, the therapeutic proteins segment was accounted for the highest revenue generator in 2021. Therapeutic biologics market is further segmented by region: Asia Pacific, Europe, North America, MEA (Middle East and Africa), Latin America. North America is estimated to account for the largest share of the global therapeutic biologics market.

By product:

• therapeutic proteins
• vaccines
• others

By region:

• Asia Pacific
• Europe
• North America
• MEA (Middle East and Africa)
• Latin America

The report has also analysed the competitive landscape of the global therapeutic biologics market with some of the key players being Amgen Inc., Baxter International Inc., China Biologic Products Holdings, Inc., CSL Ltd., Eli Lilly and Company, GlaxoSmithKline plc (GSK plc), Grifols, S.A., Kedrion S.p.A., Novartis AG, Octapharma AG, Reliance Life Sciences, Roche Holding AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global therapeutic biologics market.
• To classify and forecast the global therapeutic biologics market based on product, region.
• To identify drivers and challenges for the global therapeutic biologics market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global therapeutic biologics market.
• To identify and analyze the profile of leading players operating in the global therapeutic biologics market.

Why Choose This Report

• Gain a reliable outlook of the global therapeutic biologics market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY PRODUCT

Therapeutic proteins
Vaccines
Others

PART 6. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
MEA (Middle East and Africa)
Latin America

PART 7. KEY COMPANIES

Amgen Inc.
Baxter International Inc.
China Biologic Products Holdings, Inc.
CSL Ltd.
Eli Lilly and Company
GlaxoSmithKline plc (GSK plc)
Grifols, S.A.
Kedrion S.p.A.
Novartis AG
Octapharma AG
Reliance Life Sciences
Roche Holding AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER